0.475

1.25% -0.006

Talphera Inc (TLPH)

Overview News Price History Discussions Forecast

Talphera Inc stock is traded at $0.475, with a volume of 19,395. It is down -1.25% in the last 24 hours and down -5.75% over the past month. Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Previous Close:

$0.481

Open:

$0.4825

24h Volume:

19,395

Relative Volume:

0.47

Market Cap:

$10.46M

Revenue:

$2.82M

Net Income/Loss:

$-14.20M

P/E Ratio:

-0.5588

EPS:

-0.85

Net Cash Flow:

$-15.13M

1W Performance:

-6.88%

1M Performance:

-5.75%

6M Performance:

-24.60%

1Y Performance:

-52.17%

1-Day Range:

$0.475

$0.4897

1-Week Range:

$0.475

$0.52

52-Week Range:

$0.45

$1.19

Talphera Inc Stock (TLPH) Company Profile

Name

Talphera Inc

Sector

Healthcare (1172)

Industry

Drug Manufacturers - Specialty & Generic (82)

Phone

650-216-3500

Address

1850 GATEWAY DRIVE, SAN MATEO

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TLPH's Discussions on Twitter

Compare TLPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TLPH Talphera Inc	0.475	10.46M	2.82M	-14.20M	-15.13M	-0.85
RGC Regencell Bioscience Holdings Ltd	78.00	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	161.67	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.50	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.89	47.60B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.89	20.17B	16.54B	-1.64B	749.00M	-1.45

Talphera Inc Stock (TLPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Jul-20-20	Downgrade	Credit Suisse	Neutral → Underperform
Nov-11-19	Downgrade	Credit Suisse	Outperform → Neutral
Aug-05-19	Resumed	Credit Suisse	Outperform
Jul-10-19	Resumed	Credit Suisse	Outperform
Apr-24-19	Resumed	B. Riley FBR	Buy
Feb-15-19	Initiated	Credit Suisse	Outperform
Oct-23-18	Initiated	B. Riley FBR	Buy
Oct-13-17	Downgrade	Jefferies	Buy → Hold
Oct-13-17	Reiterated	RBC Capital Mkts	Outperform
Jul-14-17	Resumed	Jefferies	Buy
Sep-15-16	Reiterated	ROTH Capital	Buy
Aug-05-16	Downgrade	Stifel	Buy → Hold
Oct-30-15	Upgrade	Jefferies	Hold → Buy
Oct-05-15	Reiterated	ROTH Capital	Buy
Sep-02-15	Initiated	H.C. Wainwright	Buy
Jul-10-15	Resumed	ROTH Capital	Buy
May-06-15	Reiterated	Mizuho	Neutral
May-05-15	Reiterated	RBC Capital Mkts	Outperform
Mar-10-15	Reiterated	RBC Capital Mkts	Outperform
Mar-09-15	Downgrade	Mizuho	Buy → Neutral

View All

Talphera Inc Stock (TLPH) Latest News

Jun 06, 2025

Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript - MSN

Jun 06, 2025

Jun 05, 2025

talphera receives extension to meet nasdaq listing requirements - Investing.com India

Jun 05, 2025

talphera receives extension to meet nasdaq listing requirements By Investing.com - Investing.com South Africa

Jun 05, 2025

Talphera Granted Extension for Nasdaq Compliance - TipRanks

Jun 05, 2025

May 29, 2025

Financial Review: Talphera (NASDAQ:TLPH) & Alterity Therapeutics (NASDAQ:ATHE) - Defense World

May 29, 2025

May 17, 2025

Talphera’s Strategic Advancements and Financial Stability Reinforce Buy Rating - TipRanks

May 17, 2025

May 15, 2025

Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing - MSN

May 15, 2025

Talphera, Inc. Earnings Call: Strategic Adjustments and Financial Progress - TipRanks

May 15, 2025

TLPH Prepares to Finalize NEPHRO CRRT Registration Trial | TLPH Stock News - GuruFocus

May 15, 2025

Talphera: Q1 Earnings Snapshot - Greenwich Time

May 15, 2025